Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBITDA (2020 - 2025)

Historic EBITDA for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$12.3 million.

  • Tarsus Pharmaceuticals' EBITDA rose 4613.07% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year increase of 3938.68%. This contributed to the annual value of -$115.4 million for FY2024, which is 1505.51% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' EBITDA stood at -$12.3 million, which was up 4613.07% from -$20.4 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' EBITDA ranged from a high of $10.4 million in Q1 2021 and a low of -$41.9 million during Q4 2023
  • In the last 5 years, Tarsus Pharmaceuticals' EBITDA had a median value of -$22.5 million in 2022 and averaged -$20.3 million.
  • In the last 5 years, Tarsus Pharmaceuticals' EBITDA soared by 63019.93% in 2021 and then tumbled by 44635.21% in 2023.
  • Tarsus Pharmaceuticals' EBITDA (Quarter) stood at -$14.9 million in 2021, then grew by 8.0% to -$13.7 million in 2022, then plummeted by 206.64% to -$41.9 million in 2023, then soared by 44.43% to -$23.3 million in 2024, then surged by 47.01% to -$12.3 million in 2025.
  • Its EBITDA was -$12.3 million in Q3 2025, compared to -$20.4 million in Q2 2025 and -$25.2 million in Q1 2025.